# NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
> **ANDA217738** · Abbreviated New Drug Application (Generic) · Sponsor: SCIEGEN PHARMS · Approved 2023-10-11
## Drug
- **FDA Application Number:** ANDA217738
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
- **Generic name:** NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
- **Active ingredients:** ESOMEPRAZOLE MAGNESIUM; NAPROXEN
- **Dosage form:** TABLET, DELAYED RELEASE
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** SCIEGEN PHARMS
- **Manufacturer:** ScieGen Pharmaceuticals, Inc
- **First approval:** 2023-10-11
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217738)
---
*AI Analytics · CC0 1.0*